← Back to Clinical Trials
Recruiting NCT06652321

NCT06652321 Endothelial Side Up Inverted Femtosecond Laser Assisted DSAEK

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06652321
Status Recruiting
Phase
Sponsor Dar El Oyoun Hospital
Condition Pseudophakic Bullous Keratopathy
Study Type INTERVENTIONAL
Enrollment 15 participants
Start Date 2022-01-01
Primary Completion 2024-11-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Endothelial Side Up Femtosecond Laser Assisted DSAEK

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 15 participants in total. It began in 2022-01-01 with a primary completion date of 2024-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate the clinical outcomes (pos toperative best corrected visual acuity, endothelial count) and anatomical results (interface smoothness) of DSAEK with Femto LDV-prepared grafts from the endothelial side.

Eligibility Criteria

Inclusion Criteria: Patients with Fuchs' endothelial dystrophy Patients with bullous keratopathy secondary to intraocular surgeries, iridocorneal endothelial syndrome, or viral keratitis Exclusion Criteria: Bullous keratopathy secondary to glaucoma or ocular trauma Corneal stromal scarring or opacities Diseases not affecting the corneal endothelium, including corneal ectasia (e.g., keratoconus, keratoglobus, pellucid marginal degeneration) Epithelial, Bowman layer/anterior stromal, and stromal dystrophies Hypotonic eyes Retinal diseases Any type of optic atrophy

Contact & Investigator

Central Contact

Tarek H Nasr, Msc

✉ tarekhaytham@gmail.com

📞 +201002412992

Frequently Asked Questions

Who can join the NCT06652321 clinical trial?

This trial is open to participants of all sexes, studying Pseudophakic Bullous Keratopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06652321 currently recruiting?

Yes, NCT06652321 is actively recruiting participants. Contact the research team at tarekhaytham@gmail.com for enrollment information.

Where is the NCT06652321 trial being conducted?

This trial is being conducted at Giza, Egypt.

Who is sponsoring the NCT06652321 clinical trial?

NCT06652321 is sponsored by Dar El Oyoun Hospital. The trial plans to enroll 15 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology